Camp4 Therapeutics Corp CAMP
Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026
Camp4 Therapeutics Corp (CAMP) is a healthcare company listed in the US with a market value of about $238M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$121M, a net margin of -2276.3%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -71%.
About Camp4 Therapeutics
Camp4 Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. It was profitable in 0 of the last 3 years in our data. It spends 1092% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $5M | $3M | $652000 | $350000 |
| Net income | -$121M | -$80M | -$52M | -$49M |
| Free cash flow | -$26M | -$30M | -$46M | -$45M |
| EPS (diluted) | $-2.11 | $-1.32 | $-5.52 | $-62.40 |
| Net margin | -2276.3% | -2298.5% | -7943.4% | -14083.1% |
| ROIC | — | -83.6% | -58.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $10.22, 169% above the current price; targets range from $6.00 to $15.00; the consensus rating is “Strong buy”; expected EPS is $-1.21 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Camp4 Therapeutics pay a dividend?
Not currently.
Is Camp4 Therapeutics a good stock to buy?
We do not give buy or sell advice. Camp4 Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.